Virtu Financial LLC acquired a new position in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 18,992 shares of the biotechnology company's stock, valued at approximately $326,000.
Other large investors have also made changes to their positions in the company. Healthcare of Ontario Pension Plan Trust Fund boosted its holdings in ADMA Biologics by 13.9% in the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 658,900 shares of the biotechnology company's stock valued at $13,171,000 after purchasing an additional 80,400 shares during the period. Lord Abbett & CO. LLC bought a new stake in shares of ADMA Biologics in the third quarter valued at about $61,858,000. Raymond James Financial Inc. bought a new stake in shares of ADMA Biologics in the fourth quarter valued at about $19,076,000. EWG Elevate Inc. acquired a new stake in ADMA Biologics during the fourth quarter worth about $480,000. Finally, Citigroup Inc. increased its stake in ADMA Biologics by 251.7% during the third quarter. Citigroup Inc. now owns 387,226 shares of the biotechnology company's stock valued at $7,741,000 after acquiring an additional 277,138 shares during the period. Institutional investors and hedge funds own 75.68% of the company's stock.
ADMA Biologics Price Performance
Shares of NASDAQ:ADMA traded down $0.93 during midday trading on Monday, reaching $19.33. 2,266,960 shares of the company's stock were exchanged, compared to its average volume of 3,512,766. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. The company's 50 day simple moving average is $17.13 and its two-hundred day simple moving average is $18.16. ADMA Biologics, Inc. has a 12 month low of $5.90 and a 12 month high of $23.64. The firm has a market capitalization of $4.57 billion, a PE ratio of 68.82 and a beta of 0.60.
Analyst Upgrades and Downgrades
Separately, Cantor Fitzgerald reiterated an "overweight" rating and issued a $25.00 price objective on shares of ADMA Biologics in a research report on Tuesday, March 4th.
Check Out Our Latest Research Report on ADMA
ADMA Biologics Company Profile
(
Free Report)
ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
Recommended Stories
Before you consider ADMA Biologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ADMA Biologics wasn't on the list.
While ADMA Biologics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
